Safety and efficacy of topical, fixed‐dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial
Open Access
- 13 November 2019
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (5) , 1098-1104
Abstract
Background: Psoriasis is a disease that commonly manifests in adolescence. Up to half of adults with psoriasis develop it before the age of 20. Topical formulations containing corticosteroids and/or vitamin D3 analogs are recommended for treatment.Objective: This phase II study aimed to evaluate the safety, including any potential effect on the hypothalamic–pituitary–adrenal axis and calcium metabolism, and efficacy of fixed‐dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) (Cal/BD) gel in adolescents with psoriasis.Methods: Patients aged 12 to <17 years, with at least mild psoriasis on the body and scalp, received topical Cal/BD gel once daily for ≤8 weeks. Safety response criteria included adverse drug reactions [ADRs; any adverse event (AE) possibly or probably related to treatment as determined by the investigator; a primary response criterion] and AEs (a secondary response criterion). Only treatment‐emergent AEs (events that occurred after the first application of Cal/BD gel or events which started before this and increased in intensity after the first application of Cal/BD gel) are presented here. Efficacy response criteria included controlled disease, by physician's global assessment of disease severity (PGA), following Cal/BD gel treatment.Results: A total of 107 patients (median age 14 years; range 12–16) were enrolled and treated. Eight ADRs were observed in 7 (7%) patients and 38 (36%) patients experienced ≥1 AE. The most common AEs were headache [6 (6%) patients], nasopharyngitis [6 (6%) patients] and blood parathyroid hormone increased [4 (4%) patients]. One severe AE was reported (attempted suicide) but was considered unrelated to treatment. At the end of treatment, 58% of patients had controlled disease on the body and 69% on the scalp according to PGA.Conclusion: In this uncontrolled phase II study, Cal/BD gel was well tolerated and effective for treating scalp and body psoriasis in adolescents.Keywords
This publication has 23 references indexed in Scilit:
- Self-Management in Daily Life with Psoriasis: An Integrative Review of Patient Needs for Structured EducationNursing Research and Practice, 2012
- The influence of treatments in daily clinical practice on the Children’s Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registryBritish Journal of Dermatology, 2012
- The Burden of Childhood PsoriasisPediatric Dermatology, 2011
- Epidemiology and comorbidity of psoriasis in childrenBritish Journal of Dermatology, 2009
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2009
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasisArchives of Dermatological Research, 2006
- Prevalence and Treatment of Psoriasis in the United KingdomArchives of Dermatology, 2005
- Psoriasis assessment tools in clinical trialsAnnals of the Rheumatic Diseases, 2005
- Treatment of PsoriasisNew England Journal of Medicine, 1995